Abstract: A process for the automated classification and analysis of raw data includes the selection and use of a method suitable for analyzing the physical and chemical properties of materials such as chemical compounds. The results can then be used to optimize a process of interest, such as a chemical process. The chemical process may include a chemical reaction or a purification process including chemical and physical steps.

Abstract: A formulation includes one or more active ingredients of poor water solubility for medical or non-medical use in the rearing of animals. The formulation is suitable for administration to the animals via their drinking water. It exhibits superior stability. The formulation comprises an active ingredient, a thickener combination and water, wherein the thickener combination comprises at least one thickener selected from the following groups A, B, C and D: (A) cellulose derivatives, such as methyl cellulose, sodium carboxy methyl cellulose, (B) non-cellulosic polysaccharide thickeners such as xanthan gums, Arabic gum, (C) cross-linked polyacrylic acid polymers, (D) hydrocolloidal hydrated silicates.

Abstract: The present invention relates to the field of pharmaceutical technology and in particular to novel dosage forms of medicaments containing as active ingredients simvastatin and ezetimibe, or pharmaceutically acceptable salts thereof. The present pharmaceutical compositions are characterized in that the contact of the compositions with oxygen is substantially reduced, such as by coating the composition, providing a medicament useful for the treatment and prevention of atherosclerosis and related conditions, in an environment having an essentially reduced oxygen or humidity, respectively, content.

Abstract: The present invention relates to the method of preparing of ezetimibe and in particular to novel intermediates for its synthesis and an improved process for preparing such intermediates. Said intermediates may be obtained in high yields and purity in a fast and cost efficient manner. The present invention relates to a novel crystalline form of ezetimibe as well.

Abstract: The invention relates to pharmaceutical oral dosage forms of the active substance ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate (dabigatran etexilate) and the pharmacologically acceptable salts thereof, in particular dabigatran etexilate methanesulfonate.

Abstract: The present invention relates to new salts of perindopril, particularly to a new calcium salt and new amine salts of perindopril, to a process for their preparation and to a pharmaceutical formulations containing the new salts.

Abstract: The invention relates to a solid pharmaceutical composition comprising donepezil hydrochloride hydrate and a process for its preparation. In particular it relates to a composition and a process wherein the donepezil hydrochloride retains its polymorphic form and is therefore highly stable against conversion into other polymorphic forms.

Abstract: The present invention relates to a process for the automated classification and analysis of data, said process comprising the steps of i) selecting an analytical method for use in an analytical experiment; ii) determining working parameters and conditions for the selected method, which parameters and conditions have an effect on the results obtained by using the selected method; iii) assigning to a set of data, said set of data including a) the type of the selected method and b) a specific combination of working parameters and conditions used in the analytical experiment a unique analytical method code (Hash value); iv) applying the method characterized by said Hash value to at least one reference sample and at least one or more further samples obtained from a process for preparing said sample, in which process at least one parameter such as temperature, solvent, or ratio of reactants etc.

Abstract: A pharmaceutical formulation comprising a homogeneous mixture of (a) olanzapine or a pharmaceutically acceptable salt thereof as an active ingredient, (b) a monosaccharide and/or oligosaccharide, (c) a polysaccharide and, optionally, further ingredients.

Abstract: The present invention describes a novel process for the preparation of levocetirizine and pharmaceutically acceptable acid addition salts thereof using diglycolic acid or derivatives thereof and new intermediates used in that process.

Abstract: Processes for the preparation of clopidogrel hydrogen sulfate of polymorphic form I are described which include use of specific solvents and process measures to avoid formation of undesired by-products.

Abstract: The present invention relates to an improved process for the manufacture of olmesartan and pharmaceutically acceptable salts and esters thereof as an active ingredient of a medicament for the treatment of hypertension and related diseases and conditions.

Abstract: The invention relates to a novel and well defined Oolvate form of olanzapine which contains 2 molecules of water and 1 molecule of isopropanol per 2 molecules of olanzapine, and which can be converted into other, forms of olanzapine, in particular form (I) of olanzapine, as well as processes for preparing form (I) olanzapine.

Abstract: The present invention concerns preferably surfactant-free solid pharmaceutical formulations comprising, as an active ingredient, at least one of irbesartan and pharmaceutically acceptable salts thereof, and at least one disintegrant. Preferably, the active ingredient comprises irbesartan hydrochloride. Also, the present invention is directed to a process for the manufacture of such formulations, including a wet granulation process (A) and a direct granulation process (B).

Abstract: The present invention relates to sesquihydrate hydrochloride salt of irbesartan and pharmaceutical compositions comprising the same.

Abstract: The invention provides a process for the preparation of a sartan derivative of formula (I) (formula as filed in paper form) (I) wherein the substituents have the meaning indicated in the description, or a pharmaceutically acceptable salt thereof, comprising reacting 2-cyanophenylboronic acid or a derivative thereof with a p-halobenzyl-1H-imidazole derivative of formula (VI), (formula as filed in paper form) (VI) wherein (part of formula as filed in paper form), X, Y, R1 and R2 are as defined above, and Z is I, Br or Cl, in the presence of a transition metal catalyst and an inorganic or organic base. The invention also provides new intermediates of formula (V), (formula as filed in paper form) (V) wherein M is an alkali metal or an NR4R5R6R7 group; and of formula (II) (formula as filed in paper form) (II).

Abstract: The invention relates to a solid pharmaceutical composition comprising donepezil hydrochloride hydrate and a process for its preparation. In particular it relates to a composition and a process wherein the donepezil hydrochloride retains its polymorphic form and is therefore highly stable against conversion into other polymorphic forms.

Abstract: The present invention relates to new salts of perindopril, particularly to a new calcium salt and new amine salts of perindopril, to a process for their preparation and to a pharmaceutical formulations containing the new salts.

Abstract: The invention relates to a process for the preparation of form I of olanzapine, crystallized from a solvent mixture which comprises 2-propanol, some pseudopolymorphic forms, namely solvates of olanzapine, a new polymorphic form A of olanzapine, and processes for the preparation thereof.

Abstract: A process for preparing venlafaxine in a high yield as well as processes for producing venlafaxine hydrochloride of form I having a very high polymorphic purity are described.